Apyx Medical (NASDAQ:APYX), an advanced energy technology company proprietary to the Renuvion® helium plasma platform, reported a net loss of $1.3 million for its fourth quarter on Tuesday.
The results indicate a stabilizing financial trajectory for the Clearwater-based medical device manufacturer as it expands its footprint in the global cosmetic and rejuvenation markets.
On a per-share basis, the company reported a loss of 3 cents.
Revenue for the three-month period reached $19.2 million, driven by steady adoption of its electrosurgical generators and single-use handpieces across both domestic and international surgical suites.
The fourth-quarter performance was bolstered by recent regulatory clearances for specific clinical indications, which have allowed Apyx to more effectively market its "plasma-assisted" skin tightening solutions.
For the full year 2025, Apyx reported that its net loss narrowed significantly to $11.2 million, or 27 cents per share, compared to wider deficits in previous fiscal cycles.
Total annual revenue reached $52.8 million.
Looking ahead, Apyx issued an optimistic financial outlook for fiscal year 2026.
The company expects full-year revenue to fall in the range of $57.5 million to $58.5 million.